timeline

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
GERMANY PNH COMPETITIVE INTELLIGENCE

Iptacopan's orphan-drug status secured an established benefit and a substantial quality-of-life finding in Germany without a comparator dossier fight. PNH has no...

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
GCC PNH COMPETITIVE INTELLIGENCE

Iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary, and fewer than 15 labs across six countries can diagnose PNH. Anti-C5...

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
FRANCE PNH COMPETITIVE INTELLIGENCE

HAS restricted iptacopan to second-line use, anemic patients below 10 g/dL haemoglobin after six months on anti-C5 therapy. France's Commission de la Transparence...

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
US OBESITY COMPETITIVE INTELLIGENCE

Tirzepatide delivered 20.9% weight loss versus semaglutide's 15.3%, but Medicare Part D still excludes anti-obesity drugs for 50 million beneficiaries....

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
US NSCLC COMPETITIVE INTELLIGENCE

Pembrolizumab holds an estimated 52% share of first-line NSCLC, splitting the market into three PD-L1 cohorts ahead of its 2028 patent expiry. Four approved...

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
US MYASTHENIA GRAVIS COMPETITIVE INTELLIGENCE

Three novel mechanisms reached US gMG in 24 months, and the AChR-antibody line decides which patients the C5 class can even reach. Generalised myasthenia gravis is...

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
UK MYASTHENIA GRAVIS COMPETITIVE INTELLIGENCE

NICE rejected efgartigimod outright in 2025, leaving rozanolixizumab as the FcRn class's one still-untested bid for UK access. An estimated 7,000-10,000 UK...

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
GCC MYASTHENIA GRAVIS COMPETITIVE INTELLIGENCE

Efgartigimod reached GCC neurology centres in 2023, yet pyridostigmine and steroids still anchor treatment for more than 85% of patients. Pyridostigmine plus...

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
US MASH COMPETITIVE INTELLIGENCE

Wegovy won MASH approval in August 2025, turning a pre-launch window into a Year 0 to Year 1 retention fight against Rezdiffra. MASH, the progressive inflammatory...

@moatrx • 3 weeks ago

has logged in

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
US IGA NEPHROPATHY Competitive Intelligence

IgA nephropathy went from zero disease-specific drugs to five FDA-approved agents across four mechanisms in under five years. Until December 2021, no therapy was...

@moatrx • 3 weeks ago • comments: 0

Posted a new blog:
UK IGA NEPHROPATHY Competitive Intelligence

Budesonide and sparsentan must clear NICE's standard £20,000-30,000/QALY bar, since IgA Nephropathy is too common for the ultra-rare HST track. An estimated...

MoatRx